12 Stocks Under $5 With Biggest Upside Potential

3. Geron Corporation (NASDAQ:GERN)

Upside Potential: 163.32%

Stock Price as of January 17: $2.89

Number of Hedge Fund Investors: 29

Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company dedicated to developing and commercializing innovative therapies, including telomerase inhibitors for hematologic malignancies (blood cancers). Geron Corporation (NASDAQ:GERN) recently achieved a major milestone with the FDA approval and commercial launch of RYTELO, a first-in-class telomerase inhibitor for treating lower-risk myelodysplastic syndromes (MDS).

Geron Corporation (NASDAQ:GERN) is focusing on the commercialization of RYTELO in the  U.S. The company is working to broaden its reach by targeting more eligible patients and enhancing awareness among healthcare providers (HCPs) through educational programs and market research. Additionally, Geron Corporation (NASDAQ:GERN) is preparing for the potential European Union launch of RYTELO. The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) is currently reviewing the marketing authorization application, with completion anticipated by early 2025. Subject to approval, the company plans to launch RYTELO in select EU markets starting in 2026. To support this expansion, Geron Corporation (NASDAQ:GERN) is partnering with experienced third parties to manage key activities, including reimbursement, health technology assessments (HTA), market access, and distribution.

Geron Corporation (NASDAQ:GERN) is also advancing the pivotal Phase 3 IMpactMF trial for relapsed/refractory myelofibrosis (MF). Interim and final analyses are expected in 2026 and 2027, respectively. A successful outcome from this trial could significantly expand RYTELO’s market potential and establish its position as a transformative treatment for hematologic malignancies.